Zymeworks Bc Inc.

Zymeworks Inc.

Gerald J Rowse

James R Rich

Stuart Daniel Barnscher

Rupert H Davies

Vincent K C Fung

Kevin Hamblett

Diana F Hausman

Rose Kamyee Lai

Patrick Kaminker

Neil C Josephson

Described herein is a method of treating biliary tract cancer (BTC) comprising administering a bispecific antigen-binding construct targeting HER2 or a bispecific antigen-binding construct targeting HER2 linked to an auristatin analogue (ADC) to a subject.

Methods of using a bispecific antigen-binding construct targeting HER2 for the treatment of biliary tract cancers

Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (<3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR ≥3.9 when administered at the same toxin dose.

Anti-HER2 biparatopic antibody-drug conjugates and methods of use

Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (&#x3c;3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR&#x2265;3.9 when administered at the same toxin dose.

Growing community of inventors

New Westminster, Canada

Gerald J Rowse